S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:AYTU

Aytu BioPharma (AYTU) Stock Price, News & Analysis

$3.04
-0.04 (-1.30%)
(As of 03/28/2024 ET)
Today's Range
$3.01
$3.12
50-Day Range
$2.46
$3.28
52-Week Range
$1.38
$3.50
Volume
15,205 shs
Average Volume
19,862 shs
Market Capitalization
$16.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Aytu BioPharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
64.5% Upside
$5.00 Price Target
Short Interest
Bearish
6.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
0.94mentions of Aytu BioPharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.05 out of 5 stars

Medical Sector

379th out of 938 stocks

Pharmaceutical Preparations Industry

172nd out of 425 stocks

AYTU stock logo

About Aytu BioPharma Stock (NASDAQ:AYTU)

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

AYTU Stock Price History

AYTU Stock News Headlines

Aytu BioPharma Inc AYTU
Seelos drops as lead drug fails in ALS trial
Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
Q2 2024 Aytu Biopharma Inc Earnings Call
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Earnings Preview: Aytu BioPharma
Aytu BioPharma earnings: here's what to expect
See More Headlines
Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AYTU
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+60.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-17,050,000.00
Pretax Margin
-17.43%

Debt

Sales & Book Value

Annual Sales
$107.40 million
Cash Flow
$1.00 per share
Book Value
$10.41 per share

Miscellaneous

Free Float
5,326,000
Market Cap
$17.38 million
Optionable
Not Optionable
Beta
-1.21
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joshua R. Disbrow (Age 49)
    Chairman & CEO
    Comp: $708k
  • Mr. Mark K. Oki CPA (Age 55)
    CFO, Secretary & Treasurer
    Comp: $522.84k
  • Mr. Greg Pyszczymuka (Age 45)
    Chief Commercial Officer
    Comp: $525k
  • Ms. Victoria Cordova
    Vice President of People & Culture
  • Mr. Jarrett T. Disbrow Ph.D. (Age 49)
    Chief Business Officer & President of Consumer Health
    Comp: $355k
  • Mr. Russ McMahen
    Senior Vice President of Research & Development
  • Mr. Ryan J. Selhorn CPA (Age 42)
    Executive VP of Finance & Business Optimization

AYTU Stock Analysis - Frequently Asked Questions

Should I buy or sell Aytu BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AYTU shares.
View AYTU analyst ratings
or view top-rated stocks.

What is Aytu BioPharma's stock price target for 2024?

1 brokerages have issued 1 year target prices for Aytu BioPharma's stock. Their AYTU share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price.
View analysts price targets for AYTU
or view top-rated stocks among Wall Street analysts.

How have AYTU shares performed in 2024?

Aytu BioPharma's stock was trading at $2.84 at the beginning of the year. Since then, AYTU stock has increased by 7.0% and is now trading at $3.04.
View the best growth stocks for 2024 here
.

When is Aytu BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AYTU earnings forecast
.

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma, Inc. (NASDAQ:AYTU) released its earnings results on Wednesday, February, 14th. The company reported ($0.04) EPS for the quarter. The business had revenue of $22.93 million for the quarter. Aytu BioPharma had a negative net margin of 18.27% and a negative trailing twelve-month return on equity of 41.00%.

When did Aytu BioPharma's stock split?

Aytu BioPharma shares reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

Who are Aytu BioPharma's major shareholders?

Aytu BioPharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.49%), Vanguard Group Inc. (0.49%), Goldman Sachs Group Inc. (0.25%), Goldman Sachs Group Inc. (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Greg Pyszczymuka and Joshua R Disbrow.
View institutional ownership trends
.

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AYTU) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners